Abstract
Dengue is a vector borne viral disease caused by a Flavivirus whereas the COVID-19 pandemic was caused by a highly contagious virus, SARS-CoV-2 belonging to family Coronaviridae. However, COVID-19 severity was observably less in dengue endemic countries and vice versa especially during the active years of the pandemic (2019-2021). We observed that dengue virus (DENV) antibodies (Abs) could cross-react with SARS-CoV-2 spike antigen. This resulted in SARS-CoV-2 false positivity by rapid Ab test kits. DENV Abs binding to SARS-CoV-2 receptor binding domain (and the reverse scenario), as revealed by docking studies further validated DENV and SARS-CoV-2 cross-reactivity. Finally, SARS-CoV-2 Abs were found to cross-neutralize DENV1 and DENV2 in virus neutralization test (VNT). Abs to other pathogens like Plasmodium, were also cross-reactive but non-neutralizing for SARS-CoV-2. Here, we analyse the existing data on SARS-CoV-2 cross-reactivity with other pathoge ns, especially dengue to assess its impact on health (cross-protection?) and differential sero-diagnosis/surveillance.
This article is protected by copyright. All rights reserved.
No comments:
Post a Comment